Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
July 11, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. Complete Response…
Fidelis Security Integrates With Palo Alto Networks To Deliver Enhanced Network Detection and Response in Zero Trust Environments
RIVERSIDE, Calif., July 8, 2025 /PRNewswire/ -- Fidelis Security, a leader in…
New Glassnode Report: How Bybit’s Response to the Lazarus Hack Became Crypto’s Defining Stress Test
DUBAI, UAE, July 1, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange…
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase…
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial…
Sangfor Receives Frost & Sullivan’s 2025 APAC Customer Value Leadership Recognition in the Extended Detection and Response Market
Frost & Sullivan applauds Sangfor for delivering advanced, AI-powered cybersecurity with exceptional…
Quantum Metal Recovery Inc. Responds to Besra Gold’s ASX Announcement, Initiates Legal Proceedings in Ontario
PENANG, Malaysia, June 6, 2025 /PRNewswire/ -- Quantum Metal Recovery Inc. (QMRI),…
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal…
